Human Beta-Ala-His dipeptidase(CNDP1) ELISA kit

Code CSB-EL005639HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
carnosine dipeptidase 1 (metallopeptidase M20 family)
Alternative Names
Beta Ala His dipeptidase ELISA Kit; Beta-Ala-His dipeptidase ELISA Kit; Carnosinase 1 ELISA Kit; Carnosinase1 ELISA Kit; Carnosine dipeptidase 1 (metallopeptidase M20 family) ELISA Kit; Carnosine dipeptidase 1 ELISA Kit; CN1 ELISA Kit; CNDP 1 ELISA Kit; CNDP dipeptidase 1 ELISA Kit; Cndp1 ELISA Kit; CNDP1_HUMAN ELISA Kit; CPGL2 ELISA Kit; Glutamate carboxypeptidase like protein 2 ELISA Kit; Glutamate carboxypeptidase-like protein 2 ELISA Kit; HsT2308 ELISA Kit; MGC102737 ELISA Kit; MGC10825 ELISA Kit; MGC142072 ELISA Kit; OTTHUMP00000163751 ELISA Kit; Serum carnosinase ELISA Kit; UNQ1915/PRO4380 ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates
Detection Range
0.156 ng/mL-10 ng/mL
0.04 ng/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human CNDP1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 92
Range % 86-96
1:2 Average % 101
Range % 97-105
1:4 Average % 91
Range % 85-97
1:8 Average % 94
Range % 90-98
The recovery of human CNDP1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 102 95-108
EDTA plasma (n=4) 94 87-98
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected
10 2.057 2.154 2.106 2.003
5 1.460 1.576 1.518 1.415
2.5 0.985 1.017 1.001 0.898
1.25 0.663 0.673 0.668 0.565
0.625 0.412 0.424 0.418 0.315
0.312 0.269 0.274 0.272 0.169
0.156 0.201 0.208 0.205 0.102
0 0.102 0.103 0.103  
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days

This Human CNDP1 ELISA Kit was designed for the quantitative measurement of Human CNDP1 protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 0.156 ng/mL-10 ng/mL and the sensitivity is 0.04 ng/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Catalyzes the peptide bond hydrolysis in Xaa-His dipeptides, displaying the highest activity toward carnosine (beta-alanyl-L-histidine) and anserine (beta-alanyl-3-methyl-histidine).
Gene References into Functions
  1. The distribution of the (CTG)5 homozygous genotype in the no-diabetic nephropathy (DN) and clinical-DN patients was comparable, a lower frequency was found in the biopsy proven-DN patients, particularly in females. We observed a significant trend towards high frequencies of the (CTG)5 homozygous genotype with increased time on dialysis. PMID: 28553654
  2. Considering that approximately 40 per cent of the population are homozygous for the 5L allele of (CTG) n repeat polymorphism in CNDP1 gene and seem to be less prone to develop DN, it is needed to evaluate whether the majority of diabetic patients (who do not have the 5L-5L genotype) would be benefited from supplementation with carnosine or with a more intensive monitoring PMID: 27834319
  3. Compared to healthy individuals and those with diabetes but no kidney disease, patients with diabetic nephropathy exhibited lower frequencies of 5L-5L genotype and 5L allele of CNDP1 gene, suggesting that this allele might confer protection against development of kidney disease in this population. PMID: 27834323
  4. genetic association studies in pediatric population in Germany: Data suggest that, in pediatric patients with chronic kidney disease, the nephroprotective effect of CNDP1 Mannheim genetic variant against disease progression is not restricted to patients with diabetic nephropathy. PMID: 27278783
  5. The experimentally measured higher affinity of homocarnosine for the enzyme relative to l-carnosine might be explained, at least in part, by more extensive interactions inside the monomeric and dimeric hCN1's active site. PMID: 27105448
  6. Data shows that higher carnosine content in human skeletal muscle is positively associated with insulin resistance and fasting metabolic preference for glucose. PMID: 26439389
  7. In gastrointestinal cancer, reduced plasma levels of CNDP1 associate with signs of catabolism and poor outcome. PMID: 25898255
  8. Alterations of serum carnosinase (CN1) activity has been associated with several pathological conditions, such as neurological disorders, chronic diseases and cancer PMID: 24566305
  9. This meta-analysis confirms that the carnosinase D18S880 microsatellite polymorphism is associated with daibetic nephropathy susceptibility, especially in the type 2 DM and the Caucasian population. PMID: 23402577
  10. Rs12604675-A in CNDP1 may confer susceptibility to overt proteinuria in Japanese women with type 2 diabetes. PMID: 23342076
  11. In this review, correlations between serum carnosine and carnosinase activity and polymorphism in CNDP1 gene are analyzed. The role of CNDP1 gene polymorphism the development of diabetic nephropathy and non-diabetic chronic kidney disease is discussed. PMID: 22706107
  12. Plasma levels of FLT and S100A9 proteins are up-regulated and CNDP1 levels are down-regulated in patients with glioblastoma. PMID: 23029420
  13. These findings provide nominal evidence supporting a role between CNDP1 variants and diabetic kidney disease. PMID: 21393041
  14. neither CNDP1 genotype nor the normal variation in circulating testosterone levels affects the muscular carnosine content PMID: 20865290
  15. Serum histidine dipeptide concentrations are not correlated to serum carnosinase activity PMID: 20971102
  16. CNDP1 polymorphism predicts progression to ESRD in patients with diabetic nephropathies, but only late after baseline measurements. PMID: 20711718
  17. CTG polymorphism of the CNDP1 gene does not affect survival of Chinese peritoneal dialysis subjects. PMID: 20979941
  18. Hyperglycemia enhances CNDP1 secretion and enzyme activity; data suggest that poor blood glucose control in diabetic patients might result in an increased enzyme secretion even in the presence of the (CTG)(5) allele. PMID: 20460427
  19. Association between the CNDP1 gene and diabetic nephropathy is sex specific and independent of susceptibility for type 2 diabetes. PMID: 20332346
  20. GCP II mRNA was detected in glial cells. Glial-rich regions, specifically the DLPFC and ERC white matter and the molecular and polymorphic layers in the hippocampus, express high levels of GCP II mRNA. PMID: 14560319
  21. diabetic patients with the carnosinase CNDP1 gene Mannheim variant are less susceptible for nephropathy PMID: 16046297
  22. no difference in allele or genotype frequency between centenarians & controls or between cardiovascular patients & controls; the recently identified functional carnosinase variant does not contribute to longevity or protect against coronary heart disease PMID: 16965804
  23. CPGL-B may be associated with cell growth and metastasis of HCC. PMID: 17121880
  24. This replicates the CNDP1 gene association with diabetic nephropathy (DN) that was initially detected in European Caucasians and in Arabs, and further demonstrates that the CNDP1 gene and carnosine pathway appear to play a role in susceptibility to DN. PMID: 17205963
  25. Diabetic patients homozygous for CNDP1 are protected against diabetic nephropathy. PMID: 17601991
  26. CN1-dependent susceptibility to diabetic nephropathy may at least in part be mediated by altered glucose metabolism in type 2 diabetic patients. PMID: 17601992
  27. South Asian Surinamese have a lower frequency of the 5/5 homozygous genotype, which was associated with lower carnosinase activity and genetic risk for developing diabetic nephropathy. PMID: 19577318

Show More

Hide All

Subcellular Location
Protein Families
Peptidase M20A family
Tissue Specificity
Found in serum and adult nervous central system. Absent in serum from patients with homocarnosinosis.
Database Links

HGNC: 20675

OMIM: 609064

KEGG: hsa:84735

STRING: 9606.ENSP00000351682

UniGene: Hs.400613

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St Ste 610-322 Houston, TX 77054, USA
Join Us with

Leave a message

check code
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1